Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.
about
Sphingolipids: a potential molecular approach to treat allergic inflammationUpdosing of Nonsedating Anti-histamines in Recalcitrant Chronic UrticariaBilastine: new insight into antihistamine treatment.[New treatment options for chronic pruritus].Management of chronic spontaneous urticaria in the elderly.Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria.
P2860
Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacological rationale for ...... at higher-than-standard doses.
@en
Pharmacological rationale for ...... at higher-than-standard doses.
@nl
type
label
Pharmacological rationale for ...... at higher-than-standard doses.
@en
Pharmacological rationale for ...... at higher-than-standard doses.
@nl
prefLabel
Pharmacological rationale for ...... at higher-than-standard doses.
@en
Pharmacological rationale for ...... at higher-than-standard doses.
@nl
P2860
P1476
Pharmacological rationale for ...... at higher-than-standard doses.
@en
P2860
P356
10.1111/J.1468-3083.2011.04185.X
P577
2011-07-29T00:00:00Z